A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Servier
Pfizer
Eli Lilly and Company
ImmunityBio, Inc.
Bristol-Myers Squibb
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
AstraZeneca
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Gilead Sciences
Pfizer
Hoffmann-La Roche
Novartis
UNICANCER
Merck Sharp & Dohme LLC
AstraZeneca
University of Rochester
Merck Sharp & Dohme LLC
Genentech, Inc.
Gilead Sciences
Eikon Therapeutics
University of Utah
Merck Sharp & Dohme LLC
University of Southern California
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Genelux Corporation
Merck Sharp & Dohme LLC
AbbVie
Trishula Therapeutics, Inc.
Iovance Biotherapeutics, Inc.